13F Holdings
中文EN

RGC Regencell Bioscience Holdings Ltd Annual reports only

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1829667

Financial factors as of 2026-06-30 (FY2026), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-226.5%
TTM EPS YoY-229.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-128.5%
ROA-114.2%
ROIC (approx.)-1,159.2%
Asset turnover—

Leverage & solvency

Liabilities / assets9.4%
Debt / equity0.00x
Current ratio10.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.66x
Accruals ratio-39.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue—————
R&D expense$1.30M$948,289$1.07M$1.58M$2.51M
SG&A expense$10.42M$2.81M$3.55M$4.43M$5.08M
Operating income-$11.72M-$3.77M-$4.74M-$6.27M-$7.62M
Pretax income-$11.70M-$3.58M-$4.36M-$6.06M-$7.59M
Net income-$11.70M-$3.58M-$4.30M-$5.87M-$7.45M
EBITDA-$11.64M-$3.69M-$4.43M-$5.98M-$7.47M
EPS (basic)-2.37-0.72-0.87-1.19-0.58
EPS (diluted)-2.37-0.72-0.87-1.19-0.58
Weighted avg. shares (diluted)494.60M494.49M494.49M494.49M12.81M
Balance sheet
Cash & equivalents$14.19M$2.42M$2.96M$1.56M$6.42M
Short-term investments—$2.48M$5.00M$10.00M$10.00M
Current assets$14.22M$4.90M$8.11M$11.62M$16.44M
PP&E, net$135,112$215,434$141,734$440,829$712,594
Total assets$14.73M$5.76M$8.44M$12.62M$18.02M
Current liabilities$1.32M$663,673$193,578$606,914$577,764
Total liabilities$1.38M$895,308$219,512$632,320$938,032
Shareholders' equity$13.35M$4.86M$8.22M$12.03M$17.07M
Shares outstanding495.88M494.49M494.49M13.01M13.01M
Cash flow statement
Operating cash flow-$7.70M-$3.11M-$4.00M-$4.96M-$5.27M
Capital expenditure—$152,689$5,376$27,392$780,876
Free cash flow—-$3.27M-$4.01M-$4.99M-$6.05M
Investing cash flow$2.50M$2.69M$5.24M$58,978-$10.78M
Financing cash flow$16.95M—$102,282$134,913$22.41M
Depreciation & amortization$80,908$77,692$305,780$293,135$150,147
Stock-based compensation$3.23M$244,808$449,311$922,623$2.76M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.